They attributed this difference to shorter waiting times in the LDLT group, which may prevent disease progression. However, as shown in table 5, the preoperative variables of the two groups were comparable in the present study. This may be why outcomes after emergency LDLT and emergency DDLT were similar in the present study. In our study, we excluded patients with malignant liver diseases to eliminate the negative influences of tumour recurrence as a late complication. However, there are also some limitations in our study. We did not compare the incidence of rejection between the two groups. Although previous investigations report a lower rejection rate for LDLT than DDLT in the paediatric and adult patient populations, this topic is still controversial and deserves further study. Additionally, the mean follow-up period of the LDLT group was shorter than the DDLT group. This was because of more DDLTs were performed in 2005. In 2005, we performed 103 liver transplantations for patients with TH-302 benign endstage liver disease, including 18 LDLTs and 85 DDLTs. The proportion of LDLT increased in the later transplant period. Although the conclusions we report include all liver transplantations from 2005 to 2011 for patients with benign end-stage liver disease, the mean follow-up time specifically for the LDLT group is much shorter than the DDLT group. We suggest that many postoperative complications occurred in the early postoperative period. For instance, the late biliary complications occurred from 4 to 26 postoperative months. This was supported by the findings from the paediatric liver transplantation group. Berrocal et al. reported that most vascular and biliary complications after paediatric liver transplantation occur in the early postoperative period, especially the first 3 postoperative months. However, the mean follow-up period for the LDLT group was 34.58621.53 months. We thus believe the difference in the length of the follow-up period may not be very influential in the final conclusion. In conclusion, we report there is a role for LDLT for patients with benign liver diseases. Patients undergoing LDLT have similar outcomes to patients undergoing DDLT. Specifically, outcomes include a similar incidence of severe postoperative complications, a vascular complication rate, HBV recurrence rate and long-term survival rate. Emergency LDLT can achieve similar long-term survival rates to emergency DDLT. Additionally, similar biliary complication rates between LDLT and DDLT during a long-term follow-up period was observed, although it was noted that patients who underwent LDLT may suffer from a higher incidence of immediate biliary complication. Hypercholesterolemia is a contributing factor to atherosclerosis and consequent cardiovascular and cerebrovascular disease. Clinically, statins effectively lower plasma cholesterol by inhibiting HMG-CoA reductase activity. Nevertheless, some patients under statin treatment can not tolerate statins well or do not reach the low-density lipoprotein-cholesterol goal recommended.